Drug and Gene Delivery Systems Market Worth $786.9 Billion by 2025

| January 3, 2017

article image
The global drug and gene delivery systems market is expected to reach USD 786.9 Billion by 2025, according to a new report by Grand View Research, Inc. Rising investment by the market players to develop innovative drug delivery systems to cater to the demand by the patients, as well as to increase the bioavailability at minimum quantity of active pharmaceutical ingredient is driving the market growth, the report states. Additionally, increasing focus on R&D of gene delivery systems owing to the high growth potential of gene therapy for the treatment of a wide range of diseases is expected to fuel the market growth in the future.

Spotlight

Dermal Laboratories Limited

Dermal Laboratories Limited is a Pharmaceuticals company located in Old Station Rd, Loughton, United Kingdom. Diomed Developments is a remarkable healthcare group for many reasons. Unusually for a successful business in an industry dominated by giant multi-nationals, Diomed is an independent, privately owned company. The majority of the group’s business is conducted in the UK, where several products rank as ‘brand leaders’ in their respective categories. Also, unusually for such a relatively small company, Diomed’s infrastructure reflects full vertical integration – comprising research, development, manufacture, marketing and distribution. Diomed Developments was founded in 1963 by a London physician. Originally under the name 'Dermal Laboratories', the Company set out to develop, market and distribute pharmaceutical products to dermatologists. As the business grew rapidly during the late 1960s, the Company's focus broadened from speciality products for dermatologists to include prescr

OTHER ARTICLES

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 3, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Coronavirus Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt

Article | April 3, 2020

Rene Roach fired off a quick email in late March for an update on a colorectal cancer clinical trial for which she hoped to qualify. Worried about the coronavirus, she asked, almost as an afterthought, whether the study had been put on hold because of the pandemic.The answer crushed her: It had been. "That's when COVID-19 shut down everything," says Roach, 50, of Germantown, Md. Roach assumed that there would be workarounds for patients like her, who have stage IV cancer. These patients often depend on clinical trials as their best chance to knock cancer out when other therapies have failed. For now, she's being treated with traditional chemotherapy, but she was counting on the drug cocktail from the clinical trial. She figures if chemo was going to rid her body of cancer for good, it would have done so already.

Read More

Enabling Active Pharma Ingredients for Batch Balancing and Integration to SAP EWM

Article | April 3, 2020

Batch and its Classification system are two most potent weapons used in Chemical, Pharma or Medical life science industry to record the potency of a batch or technically called as Active Pharma Ingredients(API). These material consist of one or more active ingredients, concentrates, carrier materials, or impurities, and so on. The potency of the active ingredients varies from batch to batch. The active ingredient is the substance of greatest interest in the bill of materials, the proportion of which may vary from batch to batch. Therefore, during creation of a process order, the system must be able to select and adjust the batches needed to obtain the required amount of active ingredient. Take an example of a drug hydroxychloroquine which is used as potent weapon to fight COVID-19. This drug is manufactured by using API, however, the Potency of this API material vary from batch to batch. To map this kind of requirement in SAP ERP, SAP calls it as Material Quantity Calculation.

Read More

How Pharma Companies Can Scale Up Their Knowledge Discovery with Semantic Similarity Search

Article | April 3, 2020

Pharma has deep roots in human history with centuries of folk pharmaceutical knowledge offering a hit-and-miss range of natural remedies. But the industry as we know it today actually emerged in the second half of the 19th century when the world’s first factory for the sole production of medicines was found. By the late 19th and early 20th century, some chemical companies had already begun using research labs to explore the medical applications for their products. Fast forward to today and the pharmaceutical sector is a global trillion-dollar industry. However, to ensure the safety and efficacy of drugs, the process of drug discovery and development is under extensive scrutiny and control on both national and global levels.

Read More

Spotlight

Dermal Laboratories Limited

Dermal Laboratories Limited is a Pharmaceuticals company located in Old Station Rd, Loughton, United Kingdom. Diomed Developments is a remarkable healthcare group for many reasons. Unusually for a successful business in an industry dominated by giant multi-nationals, Diomed is an independent, privately owned company. The majority of the group’s business is conducted in the UK, where several products rank as ‘brand leaders’ in their respective categories. Also, unusually for such a relatively small company, Diomed’s infrastructure reflects full vertical integration – comprising research, development, manufacture, marketing and distribution. Diomed Developments was founded in 1963 by a London physician. Originally under the name 'Dermal Laboratories', the Company set out to develop, market and distribute pharmaceutical products to dermatologists. As the business grew rapidly during the late 1960s, the Company's focus broadened from speciality products for dermatologists to include prescr

Events